Stakeholder Perspectives on the Current and Future of Additive Manufacturing in Healthcare

Abstract

Additive manufacturing (AM) technologies have disrupted many supply chains by making new designs and functionalities possible. The opportunity to realize complex customized structures has led to significant interest within healthcare; however, full utilization critically requires the alignment of the whole supply chain. To offer insights into this process, a survey was conducted to understand the views of different medical AM stakeholders. The results highlighted an agreement between academics, designers, manufacturers, and medical experts, that personalization and design control are the main benefits of AM. Interestingly, surface finish was consistently identified as an obstacle. Nevertheless, there was a degree of acceptance that post-processing was necessary to achieve appropriate quality control. Recommendations were made for extending the use of in situ process monitoring systems to support improved reproducibility. Variations in the future vision of AM were highlighted between stakeholder groups and areas of interest for development noted for each stakeholder. Collectively, this survey indicates that medical stakeholders agree on the capabilities of AM but have different priorities for its implementation and progression. This highlights a degree of disconnection among the supply chain at a ground level; thus, collaboration on AM specific standards and enhancement of communication between stakeholders from project inception is recommended.

Cell Electrospinning: A Mini‐Review of the Critical Processing Parameters and Its Use in Biomedical Applications

“…Therefore, considerations of customized tissue production seem as reasonable as ever for future clinical medicine. [2,3] Over the years, various approaches to developing synthetic tissues have been proposed. These approaches can be categorized based on the generation process, namely non-jet and jet-based approaches.…”

“…Therefore, considerations of customized tissue production seem as reasonable as ever for future clinical medicine. [ 2 , 3 ]…”